Top Markets
#1 Nesa Nesa +824.17%
#2 Cortex Cortex +68.92%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.66%
#4 QuantixAI QuantixAI +24.05%
#5 EXOD EXOD +22.78%
#6 OpenEden OpenEden +20.79%
#7 Palladium Network Palladium Network +18.96%
#8 Pons Pons +17.38%
#9 Instadapp Instadapp +16.92%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +15.52%
Coin of the day
Nesa Nesa
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Prometheus Biosciences, Inc. Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc.

RXDX
Classificação em ações #3433
Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused... Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused on discovering, developing, and commercializing innovative therapeutics and complementary diagnostic products, mainly targeting inflammatory bowel diseases (IBD). Its flagship therapeutic candidate, PRA023, is a humanized IgG1 monoclonal antibody currently undergoing Phase IIa clinical trials. This investigational treatment is being evaluated for its potential in addressing ulcerative colitis and Crohn's disease, both forms of IBD, as well as systemic sclerosis-associated interstitial lung disease. Beyond its lead asset, Prometheus maintains an active development pipeline featuring several other programs targeting IBD and other immune-mediated conditions: PR600: An anti-tumor necrosis factor monoclonal antibody (mAb) for IBD. PR300: A small molecule G-protein coupled receptor modulator specifically for IBD. PR1100: An anti-cytokine receptor mAb with applications in IBD and various other immune disorders. PR1800: An anti-chemokine mAb focused on IBD. PR2100: An anti-inflammatory cytokine mAb also aimed at IBD. Furthermore, the company has forged key alliances, including a diagnostic development and collaboration pact with Takeda Pharmaceutical Company Limited, a co-development and manufacturing arrangement with Dr. Falk Pharma GmbH, a licensing agreement with Cedars-Sinai Medical Center, and a strategic partnership with Millennium Pharmaceuticals, Inc. Tracing its origins, the company was initially incorporated in 2016 as Precision IBD, Inc., before rebranding to Prometheus Biosciences, Inc. in October 2019. Its corporate headquarters are situated in San Diego, California.
Preço da ação
$199.92
Última sincronização: 2023-06-15
Valor de mercado
$5.39B
Variação (1 dia)
0.09%
Variação (1 ano)
0.00%
País
US
Negociar Prometheus Biosciences, Inc. (RXDX)

Categoria

Healthcare
Margem Operacional de Prometheus Biosciences, Inc. (RXDX)
Margem Operacional em 2026 TTM: 0.00%
De acordo com os relatórios financeiros mais recentes e o preço das ações da Prometheus Biosciences, Inc., a margem operacional atual (TTM) é 0.00%. No final de 2026, a margem operacional era 0.00%.
Histórico da Margem Operacional da Prometheus Biosciences, Inc. de 2026 a 2026
Margem Operacional no final de cada ano
Ano Margem Operacional Alterar
Não há dados suficientes para as datas fornecidas.
Margem Operacional de empresas semelhantes ou concorrentes
Empresa Margem Operacional Diferença na Margem Operacional País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.